Cholera is an infection of the intestine and is caused by a bacteria found in contaminated water and food. Usually mild, the symptoms of Cholera include vomiting, diarrhea, and rapid heart rate. About 5-10% of Cholera cases become severe and can cause acute renal failure and coma. If untreated, dehydration can lead to death. Cholera is treated with rehydration and more severe cases are treated with antibiotics. There are two Cholera vaccines available in most underdeveloped countries, but they come in two doses so prevention is not immediate.
Cholera Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Cholera below!
For more information on how to use Laverne, please read the How to Guide.
We have 3042 products for the study of Cholera that can be applied to Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Cholera is also known as cholera, cholera due to vibrio cholerae (disorder), cholera - vibrio cholerae (disorder), cholera, unspecified (disorder), cholera due to vibrio cholerae, vibrio cholerae infection, cholera nos (disorder), cholera, unspecified, cholera (disorder), vibrio cholerae.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.